Virginia Commonwealth University

Research Triangle Institute

Dignity Health

University of Michigan

Dignity Health Doing Business As St. Joseph's Hospital and Medical Center and Barrow Neurological Institute

Dignity Health Doing Business As St. Joseph's Hospital Medical Center and Barrow Neurological Institute

M Imad Damaj

Hernan A Navarro

Frank Ivy Carroll

S Wayne Mascarella

Bruce Edward Blough

Ronald J Lukas

Ana Zamfira Muresan

James H Woods

F Ivy Carroll

Pauline Wanjiku Ondachi

Emily M Jutkiewicz

The invention provides hydroxybupropion analogs capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and/or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity.

Hydroxybupropion analogues for treating drug dependence

Compounds and compositions for promoting smoking cessation or decreasing tobacco use or nicotine addiction are provided. The compounds are 2'-fluoro-3&#x2032;-(substituted phenyl) deschloroepibatidine analogs. The compounds have been found to modulate neuronal nicotine acetylcholine receptors and are useful in methods for the treatment of conditions or disorders influenced by the modulation of neuronal nicotinic acetylcholine receptors.

Nicotinic receptor compounds

The invention provides hydroxybupropion analogues capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and/or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity.

Growing community of inventors

Richmond, VA, United States of America

M Imad Damaj